Jaguar Health (JAGX) reported a third-quarter loss of $9.23 per share on revenue of $2.34 million. No consensus estimate or Earnings Whisper was available, so there is no surprise to measure. Earnings improved 90.2% year over year, while revenue fell 24.0%. The per-share comparison is heavily distorted by a share count that has changed dramatically: the year-ago loss was $2,032.95 per share, and the company's own table shows a 99.5% per-share improvement. The dollar figures tell a cleaner story. The net loss narrowed to $5.8 million from $9.6 million, and from $12.7 million in the second quarter. That is the most important development: Jaguar is now a much leaner, development-focused company whose costs have come down faster than its revenue. The open question is whether the balance sheet can carry it to an MVID filing without further heavy dilution.
The quality of the improvement deserves scrutiny.
The operating loss improved by a more modest $1.2 million, to $6.0 million. The cause was cost savings, not top-line strength. Sales and marketing expense nearly vanished, falling to about $51,000 from $2.0 million after the field force was dissolved under the Future Pak out-license. R&D and G&A were essentially flat.
Much of the bottom-line gain came from below the operating line:
- Fair-value losses on royalty interests and notes shrank to $96,000 from $2.3 million.
- A $558,000 gain on extinguishment of the Streeterville note added to results.
Revenue quality is also thin. License revenue jumped to $1.79 million, but the only recurring license stream the release describes is a roughly $42,000 quarterly fee from a European partner. The release separately notes that Jaguar met the conditions in August to collect the roughly $1.8 million Future Pak holdback, though it does not explicitly tie that payment to the quarter's license line. Meanwhile, net product revenue, now mostly cost-plus Mytesi supply to Future Pak, was just $551,000. That compares with about $1.2 million in the second quarter and $3.0 million a year ago. The call framed product revenue as running around $1.2 million per quarter, so the third-quarter figure falls well short of that run rate. Because Future Pak is private and does not report Mytesi sales, investors have little visibility into end demand.
On the call, the tone improved, and the narrative centered on execution. Management highlighted:
- **Debt reduction:** more than $10 million of debt paid down in the quarter.
- **Recurring EBITDA:** a non-GAAP recurring EBITDA loss of about $5.0 million, versus $8.4 million in the second quarter and roughly $9.0 million a year earlier.
- **MVID trial progress:** all randomized patients in the pediatric MVID pivotal trial are now in the treatment-only extension phase.
- **NDA timing:** the mid-2027 target for the NDA was reaffirmed.
- **Regulatory plans:** management firmed up its language to a stated plan to apply for breakthrough therapy designation in 2027, which it suggested could support approval by the end of 2027.
- **New data and market sizing:** preliminary data from a third-party adult SBS-IF pilot presented at ACG were positive, and the cited third-party MVID market estimate doubled to more than $2 billion by 2032.
- **Animal health:** Neonorm Dog is now live on Amazon.
Bears have legitimate ammunition, however:
- **Dilution:** the debt paydown relied partly on issuing common stock to Streeterville.
- **Timeline slippage:** the second-quarter goal of a clinical NDA package by end-2026 was not repeated, and the NDA itself has drifted from first-half 2027 to mid-2027 over successive calls.
- **Small data set:** the filing rests on a single-digit number of patients.
- **No runway disclosure:** no cash balance or runway was given, even as the company burns roughly $5 million per quarter on a recurring EBITDA basis.
- **Inconsistent milestone figures:** the Future Pak milestone figure has been cited as about $20 million on one call and up to $17 million on another.
The shift in language from "identifying a partner" to "evaluating strategic alternatives," with updates promised soon, cuts both ways. It may signal partnering optionality, but it can also be read as a sign of financing pressure.
The market context is thin. No current price, sentiment reading, or trend data was available. The stock opened at $0.87 after the August report, while the 200-day moving average stands at $17.85. That gap is difficult to interpret cleanly given the apparent capital-structure changes, but either way it reflects a stock that has been punished severely over the past year. That history fits a company whose equity has repeatedly been used as currency.
The bottom line is that Jaguar delivered a genuinely leaner quarter. Losses narrowed meaningfully, debt came down, and the MVID program advanced. Still, the headline improvement leans on cost cuts, non-operating items, and license income unlikely to recur, while the core product line keeps shrinking. The investment case now rests almost entirely on crofelemer in rare intestinal failure and on how Jaguar funds the path to a mid-2027 NDA. Until management discloses its cash runway and the outcome of its strategic review, dilution risk remains as central to the story as the clinical progress.